PROVETOP

Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein

Catalog No: KRASG12C-HP001

Species
Human
Expression System
HEK293
Tag
His

Product overview

Recombinant Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer Protein is expressed from HEK293 with His tag at the C-terminus. It contains Gly25-Thr305(HLA-A*11:01), Ile21-Met119(B2M) and VVVGACGVGK peptide (accession: AAV53343.1(HLA-A*11:01) & P61769(B2M) &VVVGACGVGK).

Product Details

Molecular Aliases
MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD
Protein Length
Gly25-Thr305
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 48.40 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
State
Liquid
Storage Conditions
Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Data Display

Bis-Tris PAGE
KRASG12C-HP001 Bis-Tris-PAGE-white result

Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
KRASG12C-HP001 SEC-HPLC result

The purity of Human HLA-A*11:01&B2M&KRAS G12C (VVVGACGVGK) Monomer is greater than 95% as determined by SEC-HPLC.

Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

References

  1. (1) Wu HZ, Xiao JQ, Xiao SS, Cheng Y. KRAS: A Promising Therapeutic Target for Cancer Treatment. Curr Top Med Chem. 2019;19(23):2081-2097. doi: 10.2174/1568026619666190905164144. PMID: 31486755.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support